



Prescription Drug Coverage Determination Form

Antiviral

Rebetol® (ribavirin oral solution), Ribasphere®, Ribapak®, Ribatab® and ribavirin

Please fax the completed form to Mercy Health Plans' Pharmacy Department at 314-214-8201 or 1-800-647-2240.

Patient Information

Patient Name: _____ Date of Birth: _____
Subscriber ID#: _____
Address _____ City _____ State _____ Zip Code _____

Physician Information

Name: _____ Specialty: _____ Tax ID#: _____
Office Address _____ City _____ State _____ Zip Code _____
Telephone: _____ Fax: _____ Contact Person _____

Physician Signature (REQUIRED): _____ Date _____

Medication Information (requests for non-formulary agents will be considered for members having a documented failure or contraindication to preferred agents.)

Medication name: _____ J-code: _____
Dose: _____ Directions: _____
Expected Duration of Therapy: _____

Prior Authorization Criteria:	
1. Does the patient have a diagnosis of chronic hepatitis C virus infection?	<input type="checkbox"/> Yes <input type="checkbox"/> No
If yes:	
▪ Does the patient have signs of chronic hepatitis on liver biopsy demonstrated by portal or bridging fibrosis, moderate inflammation, and necrosis?	<input type="checkbox"/> Yes <input type="checkbox"/> No
▪ Does the patient have cirrhosis of the liver as evidence by radiological data (CT scan, MRI, ultrasound) or clinical data (e.g. variceal bleed, hypersplenism)?	<input type="checkbox"/> Yes <input type="checkbox"/> No
▪ Does the patient have extrahepatic complications?	<input type="checkbox"/> Yes <input type="checkbox"/> No
2. Will the patient be taking an alfa interferon product (e.g. Intron A, Roferon A, Pegasys, PEG-Intron) concurrently with ribavirin therapy?	<input type="checkbox"/> Yes <input type="checkbox"/> No
3. Does the patient have detectable levels of Hepatitis C RNA (a viral load) in the serum?	<input type="checkbox"/> Yes <input type="checkbox"/> No
4. Has the patient received up to 4 months of ribavirin therapy previously?	<input type="checkbox"/> Yes <input type="checkbox"/> No

If yes:		
▪ Did the patient have detectable levels of Hepatitis C RNA (a viral load) in the serum after or at the end of the initial treatment period?	<input type="checkbox"/> Yes	<input type="checkbox"/> No
▪ Did the patient show a 2-log decrease in viral load?	<input type="checkbox"/> Yes	<input type="checkbox"/> No
5. Does the patient have a history of unstable heart disease?	<input type="checkbox"/> Yes	<input type="checkbox"/> No
6. Does the patient have a hemoglobin <8.5 g/dL?	<input type="checkbox"/> Yes	<input type="checkbox"/> No
7. Does the patient have a creatinine clearance less than 50 ml/min?	<input type="checkbox"/> Yes	<input type="checkbox"/> No
8. Is the patient or partner of the patient pregnant?	<input type="checkbox"/> Yes	<input type="checkbox"/> No
9. Does the patient have the diagnosis of a hemoglobinopathy, such as thalassemia major or sickle-cell anemia?	<input type="checkbox"/> Yes	<input type="checkbox"/> No
10. Is the patient Genotype-1?	<input type="checkbox"/> Yes	<input type="checkbox"/> No
11. Was the patient treated for Hepatitis C infection before and has now relapsed?	<input type="checkbox"/> Yes	<input type="checkbox"/> No

Please provide any additional history or medical information that may support coverage (attach office notes as necessary): _____

Note: If approved coverage will be as specified in above criteria or through the end of the year (December 31, 20xx). Some medications may be subject to quantity limitations or restricted to certain pharmacies.